KR20110097923A

KR20110097923A - 항-지질 항체 결정 구조를 이용한 항체 설계

항-지질 항체 결정 구조를 이용한 항체 설계 Download PDF

Info

Publication number: KR20110097923A
Authority: KR; South Korea
Prior art keywords: antibody; lipid; antibodies; amino acid; optionally
Prior art date: 2008-12-05
Legal status : Withdrawn

Application number

KR1020117015390A

Other languages

English (en)

Korean (ko)

Inventor

로저 에이. 삽바디니

조나단 마이클 오즈시아크

톰 헉스포드

Original Assignee

엘파스, 인크.

Priority date

2008-12-05

Filing date

2009-12-04

Publication date

2011-08-31

2009-12-04 Application filed by 엘파스, 인크. filed Critical 엘파스, 인크.

2011-08-31 Publication of KR20110097923A publication Critical patent/KR20110097923A/ko

Status Withdrawn legal-status Critical Current

Links

239000013078 crystal Substances 0.000 title claims abstract description 24
238000013461 design Methods 0.000 title abstract description 8
150000002632 lipids Chemical class 0.000 claims abstract description 209
230000027455 binding Effects 0.000 claims abstract description 187
238000000034 method Methods 0.000 claims abstract description 134
230000000975 bioactive effect Effects 0.000 claims abstract description 103
150000003408 sphingolipids Chemical class 0.000 claims abstract description 61
239000012634 fragment Substances 0.000 claims abstract description 53
239000003446 ligand Substances 0.000 claims abstract description 30
229910052751 metal Inorganic materials 0.000 claims abstract description 23
239000002184 metal Substances 0.000 claims abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 23
238000000126 in silico method Methods 0.000 claims abstract description 7
150000002739 metals Chemical class 0.000 claims abstract description 7
108090000623 proteins and genes Proteins 0.000 claims description 91
239000000203 mixture Substances 0.000 claims description 83
125000003275 alpha amino acid group Chemical group 0.000 claims description 68
238000002965 ELISA Methods 0.000 claims description 61
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 47
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 47
230000000694 effects Effects 0.000 claims description 44
235000001014 amino acid Nutrition 0.000 claims description 37
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 36
238000004519 manufacturing process Methods 0.000 claims description 36
229940024606 amino acid Drugs 0.000 claims description 33
150000001413 amino acids Chemical class 0.000 claims description 33
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 24
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 24
150000007523 nucleic acids Chemical group 0.000 claims description 22
125000000539 amino acid group Chemical group 0.000 claims description 16
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
239000004472 Lysine Substances 0.000 claims description 11
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
239000004473 Threonine Substances 0.000 claims description 9
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 9
235000003704 aspartic acid Nutrition 0.000 claims description 9
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 9
230000001976 improved effect Effects 0.000 claims description 9
238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 9
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
235000004279 alanine Nutrition 0.000 claims description 8
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
239000004471 Glycine Substances 0.000 claims description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
238000002441 X-ray diffraction Methods 0.000 claims description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
229960000310 isoleucine Drugs 0.000 claims description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
238000000302 molecular modelling Methods 0.000 claims 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 2
238000013500 data storage Methods 0.000 claims 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
238000005457 optimization Methods 0.000 abstract description 4
DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 250
241000282414 Homo sapiens Species 0.000 description 111
210000004027 cell Anatomy 0.000 description 110
239000000427 antigen Substances 0.000 description 96
108091007433 antigens Proteins 0.000 description 95
102000036639 antigens Human genes 0.000 description 95
235000018102 proteins Nutrition 0.000 description 73
102000004169 proteins and genes Human genes 0.000 description 72
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 68
241001529936 Murinae Species 0.000 description 58
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 55
108090000765 processed proteins & peptides Proteins 0.000 description 49
238000011282 treatment Methods 0.000 description 44
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 43
108060003951 Immunoglobulin Proteins 0.000 description 42
102000018358 immunoglobulin Human genes 0.000 description 42
241001465754 Metazoa Species 0.000 description 41
201000010099 disease Diseases 0.000 description 39
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 37
230000035772 mutation Effects 0.000 description 37
102000004196 processed proteins & peptides Human genes 0.000 description 37
206010028980 Neoplasm Diseases 0.000 description 36
239000003795 chemical substances by application Substances 0.000 description 36
229920001184 polypeptide Polymers 0.000 description 36
230000014509 gene expression Effects 0.000 description 34
210000001508 eye Anatomy 0.000 description 32
238000009472 formulation Methods 0.000 description 32
229940027941 immunoglobulin g Drugs 0.000 description 32
150000001875 compounds Chemical class 0.000 description 31
239000000523 sample Substances 0.000 description 31
239000011780 sodium chloride Substances 0.000 description 30
-1 HE- Chemical compound 0.000 description 29
208000035475 disorder Diseases 0.000 description 29
239000003814 drug Substances 0.000 description 29
239000002953 phosphate buffered saline Substances 0.000 description 29
210000004408 hybridoma Anatomy 0.000 description 28
238000006467 substitution reaction Methods 0.000 description 28
230000003993 interaction Effects 0.000 description 26
239000013612 plasmid Substances 0.000 description 26
238000003556 assay Methods 0.000 description 25
239000000872 buffer Substances 0.000 description 25
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 24
102000004190 Enzymes Human genes 0.000 description 24
108090000790 Enzymes Proteins 0.000 description 24
241000699670 Mus sp. Species 0.000 description 24
239000011575 calcium Substances 0.000 description 24
230000000875 corresponding effect Effects 0.000 description 24
229940088598 enzyme Drugs 0.000 description 24
241000894007 species Species 0.000 description 24
239000013598 vector Substances 0.000 description 24
108020004414 DNA Proteins 0.000 description 23
238000000746 purification Methods 0.000 description 23
230000001225 therapeutic effect Effects 0.000 description 23
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 22
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 22
238000002360 preparation method Methods 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
230000011664 signaling Effects 0.000 description 21
230000004071 biological effect Effects 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 20
241000588724 Escherichia coli Species 0.000 description 19
239000000463 material Substances 0.000 description 19
230000033115 angiogenesis Effects 0.000 description 18
108020004707 nucleic acids Proteins 0.000 description 18
102000039446 nucleic acids Human genes 0.000 description 18
230000002441 reversible effect Effects 0.000 description 18
239000000243 solution Substances 0.000 description 18
239000000126 substance Substances 0.000 description 18
241000699666 Mus <mouse, genus> Species 0.000 description 17
201000011510 cancer Diseases 0.000 description 17
229940106189 ceramide Drugs 0.000 description 17
239000002609 medium Substances 0.000 description 17
238000002560 therapeutic procedure Methods 0.000 description 17
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 16
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 16
229910019142 PO4 Inorganic materials 0.000 description 16
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 16
229940079593 drug Drugs 0.000 description 16
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 16
239000006228 supernatant Substances 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
238000010790 dilution Methods 0.000 description 15
239000012895 dilution Substances 0.000 description 15
238000001727 in vivo Methods 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
238000011160 research Methods 0.000 description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
241000283707 Capra Species 0.000 description 14
210000004978 chinese hamster ovary cell Anatomy 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
229940072221 immunoglobulins Drugs 0.000 description 14
210000004698 lymphocyte Anatomy 0.000 description 14
239000002207 metabolite Substances 0.000 description 14
239000002773 nucleotide Substances 0.000 description 14
125000003729 nucleotide group Chemical group 0.000 description 14
239000010452 phosphate Substances 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
239000000758 substrate Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 14
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
238000010367 cloning Methods 0.000 description 13
150000002500 ions Chemical class 0.000 description 13
239000002502 liposome Substances 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
208000005590 Choroidal Neovascularization Diseases 0.000 description 12
206010060823 Choroidal neovascularisation Diseases 0.000 description 12
241000282412 Homo Species 0.000 description 12
239000012148 binding buffer Substances 0.000 description 12
239000013604 expression vector Substances 0.000 description 12
238000011534 incubation Methods 0.000 description 12
230000003287 optical effect Effects 0.000 description 12
206010035226 Plasma cell myeloma Diseases 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
238000013459 approach Methods 0.000 description 11
230000008901 benefit Effects 0.000 description 11
239000002738 chelating agent Substances 0.000 description 11
238000005755 formation reaction Methods 0.000 description 11
230000002163 immunogen Effects 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
201000000050 myeloid neoplasm Diseases 0.000 description 11
239000002243 precursor Substances 0.000 description 11
239000000047 product Substances 0.000 description 11
230000009467 reduction Effects 0.000 description 11
230000004044 response Effects 0.000 description 11
239000011734 sodium Substances 0.000 description 11
JLVSPVFPBBFMBE-HXSWCURESA-O sphingosylphosphocholine acid Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H]([NH3+])COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-O 0.000 description 11
206010064930 age-related macular degeneration Diseases 0.000 description 10
230000008859 change Effects 0.000 description 10
230000002860 competitive effect Effects 0.000 description 10
238000004132 cross linking Methods 0.000 description 10
229940127089 cytotoxic agent Drugs 0.000 description 10
230000006870 function Effects 0.000 description 10
230000013595 glycosylation Effects 0.000 description 10
238000006206 glycosylation reaction Methods 0.000 description 10
208000019622 heart disease Diseases 0.000 description 10
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
208000002780 macular degeneration Diseases 0.000 description 10
238000002703 mutagenesis Methods 0.000 description 10
231100000350 mutagenesis Toxicity 0.000 description 10
230000008569 process Effects 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
239000011347 resin Substances 0.000 description 10
229920005989 resin Polymers 0.000 description 10
229940124597 therapeutic agent Drugs 0.000 description 10
238000005406 washing Methods 0.000 description 10
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 9
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 9
239000002253 acid Substances 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
229910052791 calcium Inorganic materials 0.000 description 9
230000007423 decrease Effects 0.000 description 9
230000012010 growth Effects 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
230000002503 metabolic effect Effects 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
150000003904 phospholipids Chemical class 0.000 description 9
229920000642 polymer Polymers 0.000 description 9
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 8
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 8
229920001213 Polysorbate 20 Polymers 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
210000004899 c-terminal region Anatomy 0.000 description 8
238000012512 characterization method Methods 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
208000037765 diseases and disorders Diseases 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
210000004602 germ cell Anatomy 0.000 description 8
238000003306 harvesting Methods 0.000 description 8
230000002209 hydrophobic effect Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
235000021317 phosphate Nutrition 0.000 description 8
150000008104 phosphatidylethanolamines Chemical class 0.000 description 8
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
230000002265 prevention Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
102200082919 rs35857380 Human genes 0.000 description 8
239000007787 solid Substances 0.000 description 8
150000003410 sphingosines Chemical class 0.000 description 8
229910052720 vanadium Inorganic materials 0.000 description 8
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 7
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 7
241000894006 Bacteria Species 0.000 description 7
108091035707 Consensus sequence Proteins 0.000 description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
ZQQLMECVOXKFJK-NXCSZAMKSA-N N-octadecanoylsphingosine 1-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(O)(O)=O)[C@H](O)\C=C\CCCCCCCCCCCCC ZQQLMECVOXKFJK-NXCSZAMKSA-N 0.000 description 7
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
241000251539 Vertebrata <Metazoa> Species 0.000 description 7
241000700605 Viruses Species 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
229960002685 biotin Drugs 0.000 description 7
235000020958 biotin Nutrition 0.000 description 7
239000011616 biotin Substances 0.000 description 7
239000000969 carrier Substances 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
230000021615 conjugation Effects 0.000 description 7
238000004925 denaturation Methods 0.000 description 7
230000036425 denaturation Effects 0.000 description 7
238000001514 detection method Methods 0.000 description 7
150000004665 fatty acids Chemical class 0.000 description 7
230000004927 fusion Effects 0.000 description 7
102000005396 glutamine synthetase Human genes 0.000 description 7
108020002326 glutamine synthetase Proteins 0.000 description 7
230000016784 immunoglobulin production Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
208000014674 injury Diseases 0.000 description 7
210000003292 kidney cell Anatomy 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
229940068968 polysorbate 80 Drugs 0.000 description 7
229920000053 polysorbate 80 Polymers 0.000 description 7
238000012552 review Methods 0.000 description 7
102220040182 rs587778219 Human genes 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
238000007910 systemic administration Methods 0.000 description 7
125000003396 thiol group Chemical group [H]S* 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 6
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
108010088751 Albumins Proteins 0.000 description 6
102000009027 Albumins Human genes 0.000 description 6
206010003445 Ascites Diseases 0.000 description 6
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
108090000526 Papain Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
238000013357 binding ELISA Methods 0.000 description 6
230000005754 cellular signaling Effects 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
238000002983 circular dichroism Methods 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 6
230000002526 effect on cardiovascular system Effects 0.000 description 6
239000012636 effector Substances 0.000 description 6
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
150000002339 glycosphingolipids Chemical class 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
150000002430 hydrocarbons Chemical group 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
230000003463 hyperproliferative effect Effects 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
239000011777 magnesium Substances 0.000 description 6
SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 6
102000013415 peroxidase activity proteins Human genes 0.000 description 6
108040007629 peroxidase activity proteins Proteins 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
238000011084 recovery Methods 0.000 description 6
230000007017 scission Effects 0.000 description 6
238000000926 separation method Methods 0.000 description 6
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 6
YHEDRJPUIRMZMP-ZWKOTPCHSA-N sphinganine 1-phosphate Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)COP(O)(O)=O YHEDRJPUIRMZMP-ZWKOTPCHSA-N 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
230000000699 topical effect Effects 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000002424 x-ray crystallography Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 5
OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
239000004971 Cross linker Substances 0.000 description 5
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
238000012286 ELISA Assay Methods 0.000 description 5
206010016654 Fibrosis Diseases 0.000 description 5
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
206010029113 Neovascularisation Diseases 0.000 description 5
108010003541 Platelet Activating Factor Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000009471 action Effects 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
230000002411 adverse Effects 0.000 description 5
230000004075 alteration Effects 0.000 description 5
239000012491 analyte Substances 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
239000000356 contaminant Substances 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
229960002433 cysteine Drugs 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000012377 drug delivery Methods 0.000 description 5
230000008622 extracellular signaling Effects 0.000 description 5
230000004761 fibrosis Effects 0.000 description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
NIOYUNMRJMEDGI-UHFFFAOYSA-N hexadecanal Chemical compound CCCCCCCCCCCCCCCC=O NIOYUNMRJMEDGI-UHFFFAOYSA-N 0.000 description 5
230000028993 immune response Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
230000003053 immunization Effects 0.000 description 5
229940099472 immunoglobulin a Drugs 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
229910021645 metal ion Inorganic materials 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000037361 pathway Effects 0.000 description 5
239000012071 phase Substances 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
238000012545 processing Methods 0.000 description 5
102220118106 rs886041171 Human genes 0.000 description 5
239000001488 sodium phosphate Substances 0.000 description 5
229910000162 sodium phosphate Inorganic materials 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000001890 transfection Methods 0.000 description 5
230000008733 trauma Effects 0.000 description 5
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 4
102100033620 Calponin-1 Human genes 0.000 description 4
208000031229 Cardiomyopathies Diseases 0.000 description 4
HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
102220573621 Galectin-1_F4V_mutation Human genes 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 4
101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
206010057190 Respiratory tract infections Diseases 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
230000003321 amplification Effects 0.000 description 4
230000002491 angiogenic effect Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
229940114079 arachidonic acid Drugs 0.000 description 4
235000021342 arachidonic acid Nutrition 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000009260 cross reactivity Effects 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000000539 dimer Substances 0.000 description 4
239000006196 drop Substances 0.000 description 4
150000002066 eicosanoids Chemical class 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
150000002270 gangliosides Chemical class 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
239000004005 microsphere Substances 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
229940055729 papain Drugs 0.000 description 4
235000019834 papain Nutrition 0.000 description 4
239000002245 particle Substances 0.000 description 4
238000012510 peptide mapping method Methods 0.000 description 4
238000002823 phage display Methods 0.000 description 4
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
150000003905 phosphatidylinositols Chemical class 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
238000004366 reverse phase liquid chromatography Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
150000003409 sphingosine 1-phosphates Chemical class 0.000 description 4
108010035597 sphingosine kinase Proteins 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000008685 targeting Effects 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108090001008 Avidin Proteins 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
241000282567 Macaca fascicularis Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
241000288906 Primates Species 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
229930003827 cannabinoid Natural products 0.000 description 3
239000003557 cannabinoid Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000033077 cellular process Effects 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
230000008602 contraction Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000011143 downstream manufacturing Methods 0.000 description 3
239000012149 elution buffer Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
208000030533 eye disease Diseases 0.000 description 3
230000035876 healing Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
239000012145 high-salt buffer Substances 0.000 description 3
239000000017 hydrogel Substances 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000004068 intracellular signaling Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
150000002617 leukotrienes Chemical class 0.000 description 3
125000003473 lipid group Chemical group 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000037353 metabolic pathway Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000004001 molecular interaction Effects 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000004983 pleiotropic effect Effects 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000012562 protein A resin Substances 0.000 description 3
230000005180 public health Effects 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000004885 tandem mass spectrometry Methods 0.000 description 3
238000004448 titration Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000027 toxicology Toxicity 0.000 description 3
230000000381 tumorigenic effect Effects 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
238000011179 visual inspection Methods 0.000 description 3
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 2
YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 2
NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
HRDVWDQQYABHGH-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline hydrochloride Chemical compound Cl.CN(C)c1ccc(cc1)-c1ccc(cc1)N(C)C HRDVWDQQYABHGH-UHFFFAOYSA-N 0.000 description 2
GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
208000002381 Brain Hypoxia Diseases 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
229940124638 COX inhibitor Drugs 0.000 description 2
241000282832 Camelidae Species 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
241000282552 Chlorocebus aethiops Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
241000255925 Diptera Species 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
102000036530 EDG receptors Human genes 0.000 description 2
108091007263 EDG receptors Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
108010008177 Fd immunoglobulins Proteins 0.000 description 2
241000724791 Filamentous phage Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 2
101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
244000285963 Kluyveromyces fragilis Species 0.000 description 2
241001138401 Kluyveromyces lactis Species 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
229930184725 Lipoxin Natural products 0.000 description 2
239000006142 Luria-Bertani Agar Substances 0.000 description 2
102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 2
108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
230000004989 O-glycosylation Effects 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
241000607720 Serratia Species 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 2
102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
206010043376 Tetanus Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
206010047513 Vision blurred Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000000654 additive Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000012867 alanine scanning Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001414 amino alcohols Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000009830 antibody antigen interaction Effects 0.000 description 2
238000011091 antibody purification Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229940124691 antibody therapeutics Drugs 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229940120638 avastin Drugs 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
230000008827 biological function Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
238000007413 biotinylation Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
229940065144 cannabinoids Drugs 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
229930183167 cerebroside Natural products 0.000 description 2
150000001784 cerebrosides Chemical class 0.000 description 2
239000013522 chelant Substances 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000001142 circular dichroism spectrum Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
229960003901 dacarbazine Drugs 0.000 description 2
230000020176 deacylation Effects 0.000 description 2
238000005947 deacylation reaction Methods 0.000 description 2
230000022811 deglycosylation Effects 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
XSDVOEIEBUGRQX-RBUKOAKNSA-N dihydroceramide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC=O XSDVOEIEBUGRQX-RBUKOAKNSA-N 0.000 description 2
238000007865 diluting Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
150000004662 dithiols Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
239000000975 dye Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000005038 ethylene vinyl acetate Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000009851 immunogenic response Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000009616 inductively coupled plasma Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000005040 ion trap Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
150000002639 lipoxins Chemical class 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000013411 master cell bank Methods 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000004899 motility Effects 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
231100000219 mutagenic Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
238000001728 nano-filtration Methods 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
210000002241 neurite Anatomy 0.000 description 2
150000002812 neutral glycosphingolipids Chemical class 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
210000001322 periplasm Anatomy 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
150000003010 phosphonosphingolipids Chemical class 0.000 description 2
229950004354 phosphorylcholine Drugs 0.000 description 2
150000003019 phosphosphingolipids Chemical class 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
102220089752 rs146378222 Human genes 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
230000036573 scar formation Effects 0.000 description 2
230000037390 scarring Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000010703 silicon Substances 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
238000004467 single crystal X-ray diffraction Methods 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
125000002657 sphingoid group Chemical group 0.000 description 2
230000004137 sphingolipid metabolism Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000007858 starting material Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
MEAZTWJVOWHKJM-CIAPRIGGSA-N 1-(3-O-sulfo-beta-D-galactosyl)-N-tetracosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](OS(O)(=O)=O)[C@H]1O MEAZTWJVOWHKJM-CIAPRIGGSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 1
ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
JSFATNQSLKRBCI-VAEKSGALSA-N 15-HETE Natural products CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 1
JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 description 1
YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
BLSAPDZWVFWUTL-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid Chemical class OS(=O)(=O)C1CC(=O)NC1=O BLSAPDZWVFWUTL-UHFFFAOYSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
229940117976 5-hydroxylysine Drugs 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
241000256118 Aedes aegypti Species 0.000 description 1
241000256173 Aedes albopictus Species 0.000 description 1
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
102000016912 Aldehyde Reductase Human genes 0.000 description 1
108010053754 Aldehyde reductase Proteins 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000351920 Aspergillus nidulans Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108090000363 Bacterial Luciferases Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
240000008564 Boehmeria nivea Species 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
102000010970 Connexin Human genes 0.000 description 1
108050001175 Connexin Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
239000012623 DNA damaging agent Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
101000703517 Dictyostelium discoideum Sphingosine-1-phosphate lyase Proteins 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000588698 Erwinia Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
101150074355 GS gene Proteins 0.000 description 1
108010015133 Galactose oxidase Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
244000299507 Gossypium hirsutum Species 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 1
101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
101000939387 Homo sapiens Urocortin-3 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 1
108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
238000012695 Interfacial polymerization Methods 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
SXTAYKAGBXMACB-DPVSGNNYSA-N L-methionine sulfoximine Chemical compound CS(=N)(=O)CC[C@H](N)C(O)=O SXTAYKAGBXMACB-DPVSGNNYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
241000481961 Lachancea thermotolerans Species 0.000 description 1
241000235651 Lachancea waltii Species 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
239000004907 Macro-emulsion Substances 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
101000935589 Mus musculus Flavin reductase (NADPH) Proteins 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
101150071357 NPP2 gene Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
241000221961 Neurospora crassa Species 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000228143 Penicillium Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
240000007377 Petunia x hybrida Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
108010076986 Phytochelatins Proteins 0.000 description 1
101100080097 Phytophthora capsici NLP2 gene Proteins 0.000 description 1
241000158500 Platanus racemosa Species 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
229920000805 Polyaspartic acid Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102100030160 Protein BUD31 homolog Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
238000011530 RNeasy Mini Kit Methods 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102000042463 Rho family Human genes 0.000 description 1
108091078243 Rho family Proteins 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
241000311088 Schwanniomyces Species 0.000 description 1
241001123650 Schwanniomyces occidentalis Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000607768 Shigella Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
241000252794 Sphinx Species 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
238000003070 Statistical process control Methods 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
208000023809 Tenon cyst Diseases 0.000 description 1
241000255588 Tephritidae Species 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
240000002657 Thymus vulgaris Species 0.000 description 1
235000007303 Thymus vulgaris Nutrition 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
241001149964 Tolypocladium Species 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
241000223259 Trichoderma Species 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108010092464 Urate Oxidase Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
102100029794 Urocortin-3 Human genes 0.000 description 1
244000000188 Vaccinium ovalifolium Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
238000012452 Xenomouse strains Methods 0.000 description 1
241000235013 Yarrowia Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
IERHLVCPSMICTF-CCXZUQQUSA-N [(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-CCXZUQQUSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229940037003 alum Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
229940125644 antibody drug Drugs 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
150000001510 aspartic acids Chemical class 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
229960002707 bendamustine Drugs 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000005460 biophysical method Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
230000004611 cancer cell death Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229940030602 cardiac therapy drug Drugs 0.000 description 1
230000001451 cardiotoxic effect Effects 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
229940076006 cell cycle modulator Drugs 0.000 description 1
230000006721 cell death pathway Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
125000001549 ceramide group Chemical group 0.000 description 1
150000001783 ceramides Chemical class 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
150000004814 combretastatins Chemical class 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006854 communication Effects 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000005238 degreasing Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000188 dichroism spectroscopy Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
238000004141 dimensional analysis Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012444 downstream purification process Methods 0.000 description 1
ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
229950005454 doxifluridine Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000003596 drug target Substances 0.000 description 1
102220481278 eIF5-mimic protein 2_Y27F_mutation Human genes 0.000 description 1
230000000678 effect on lipid Effects 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
239000008394 flocculating agent Substances 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000003976 gap junction Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
238000003500 gene array Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
201000010235 heart cancer Diseases 0.000 description 1
208000024348 heart neoplasm Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
239000003276 histone deacetylase inhibitor Substances 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
229940048921 humira Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
229960004942 lenalidomide Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229940076783 lucentis Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000000207 lymphocyte subset Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
108010029942 microperoxidase Proteins 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007372 neural signaling Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
239000002353 niosome Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
229950003600 ombrabulin Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
229960003407 pegaptanib Drugs 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008255 pharmaceutical foam Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229930000756 phytoceramide Natural products 0.000 description 1
AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
229940033329 phytosphingosine Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000013155 positive regulation of cell migration Effects 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
235000013594 poultry meat Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001012 protector Effects 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000007670 refining Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
108091006091 regulatory enzymes Proteins 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
102200156936 rs28934878 Human genes 0.000 description 1
102220047535 rs587783040 Human genes 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
102000030938 small GTPase Human genes 0.000 description 1
108060007624 small GTPase Proteins 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
229960003787 sorafenib Drugs 0.000 description 1
108010066791 sphingosine-1-phosphate phosphatase Proteins 0.000 description 1
238000012421 spiking Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
229960001796 sunitinib Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004654 survival pathway Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000005469 synchrotron radiation Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
229950007866 tanespimycin Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
239000003277 telomerase inhibitor Substances 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000001585 thymus vulgaris Substances 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
239000013638 trimer Substances 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
229950008737 vadimezan Drugs 0.000 description 1
239000004066 vascular targeting agent Substances 0.000 description 1
230000006442 vascular tone Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
UGBMEXLBFDAOGL-INIZCTEOSA-N zd6126 Chemical compound C1C[C@H](NC(C)=O)C2=CC(OP(O)(O)=O)=CC=C2C2=C1C=C(OC)C(OC)=C2OC UGBMEXLBFDAOGL-INIZCTEOSA-N 0.000 description 1